Annals of Unintended Consequences: How FDA regulations undermine the biosimilar marketplace and the BPCIA

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In March 2010, as part of Affordable Care Act, Congress passed a well-conceived and critical legislative bill, the Biologic Pricing and Competition Innovation Act of 2009 (BPCIA)i. Despite its intentions, BPCIA has been instituted so that it complicates prescribing while increasing health care costs and reducing competition, rather than resulting in the anticipated benefits.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Howard S. Hochster, MD
Distinguished Professor of Medicine; Associate director for clinical research and director, GI Oncology; Rutgers Cancer Institute; Director of oncology research, RWJBarnabas Health
Michael P. Kane, RPh, BCOP
Executive director, Oncology Pharmacy Services & Research Shared Resource, Rutgers Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

FDA granted traditional approval to Merck’s pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1).
Howard S. Hochster, MD
Distinguished Professor of Medicine; Associate director for clinical research and director, GI Oncology; Rutgers Cancer Institute; Director of oncology research, RWJBarnabas Health
Michael P. Kane, RPh, BCOP
Executive director, Oncology Pharmacy Services & Research Shared Resource, Rutgers Cancer Institute

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login